OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000MG32SH7

Market Closed - Börse Stuttgart 01:18:47 08/06/2024 am IST
1.67 EUR 0.00% Intraday chart for OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL
Current month+49.11%
1 month-12.57%
Date Price Change
07/24/07 1.67 0.00%
06/24/06 1.67 +9.15%
05/24/05 1.53 +1.32%
04/24/04 1.51 +23.77%
03/24/03 1.22 +8.93%

Delayed Quote Börse Stuttgart

Last update June 08, 2024 at 01:18 am IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
Issuer Morgan Stanley
WKN MG32SH
ISINDE000MG32SH7
Date issued 26/04/2024
Strike 63.22 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.41
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.09
Lowest since issue 1.01

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
80.69 USD
Average target price
108.1 USD
Spread / Average Target
+33.96%
Consensus